KRAS and plasma cell myeloma: In fact, proteasomal protein PSMD14 showed significant selectivity for mut-KRAS cell lines in the apoptosis assay with the large panel of 28 cell lines, and chemical inhibition of proteasome function using the licensed cancer drug bortezomib (in the clinic for the treatment of multiple myeloma) confirmed a selective loss of cell viability, associated with the induction of apoptosis, in mut-KRAS cells.